{"id":94367,"date":"2023-12-05T14:08:17","date_gmt":"2023-12-05T14:08:17","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=114917"},"modified":"2023-12-05T14:08:17","modified_gmt":"2023-12-05T14:08:17","slug":"curia-recognized-on-india-pharma-outlooks-2023-list-of-top-10-cdmo-companies-in-india","status":"publish","type":"post","link":"https:\/\/jordannewsgazette.com\/curia-recognized-on-india-pharma-outlooks-2023-list-of-top-10-cdmo-companies-in-india\/","title":{"rendered":"Curia Recognized on India Pharma Outlook\u2019s 2023 List of Top 10 CDMO Companies in India"},"content":{"rendered":"
ALBANY, N.Y., Dec. 05, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been recognized as one of the top 10 CDMOs in India by India Pharma Outlook. The full list can be viewed in the November 2023 edition of the India Pharma Outlook magazine<\/a>.<\/p>\n This recognition acknowledges the contributions of Curia\u2019s Aurangabad and Hyderabad sites. The Aurangabad facility provides contract manufacturing of active pharmaceutical ingredients (APIs) and intermediates, and the Hyderabad site includes the Hyderabad Research Center with expertise in medicinal chemistry and chemical and analytical development. These sites also house Curia\u2019s quality control center and Global Shared Services (GSS) center, which support the company\u2019s global organization, enabling process standardization and scalability.<\/p>\n Curia\u2019s focus on continuous improvement for its comprehensive suite of services and investments in innovative technologies position the company as a strong partner to pharmaceutical and biotechnology companies across the drug research, development and manufacturing continuum. The report also highlights Curia\u2019s commitment to being an employer of choice, providing employees with a workplace culture rich in opportunities for professional development and recognition.<\/p>\n \u201cThis achievement is a testament to the talent and hard work from our Aurangabad and Hyderabad facilities, and it is a well-deserved honor for the team,\u201d said Philip Macnabb, CEO, Curia. \u201cOur India sites relentlessly pursue excellence and are vital to our goal of improving patients\u2019 lives.\u201d<\/p>\n India Pharma Outlook\u2019s editorial board compiled the list with a panel of judges with expertise in the industry, including CXOs and analysts. Winners were chosen for their impact on India\u2019s economy through job creation, fostering research and development and for their high-quality offerings in the pharmaceutical and biotechnology industry.<\/p>\n About Curia<\/strong> Curia Contact Information:
\nCuria is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia\u2019s nearly 4,000 employees at 27 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com<\/a>.<\/p>\n
\nViana Bhagan
\n+1 518 512 2111
\ncorporatecommunications@